首页>>文献首页>>文献正文

Sorafenib inhibits transforming growth factor β1‐Mediated Epithelial‐Mesenchymal Transition and apoptosis in mouse hepatocytes

dankan 添加于 2011/5/10 16:43:23  1644次阅读 | 0次推荐 | 0个评论

Epithelial-mesenchymal transition (EMT) is a physiological process that has been recognized to occur during the progression of an increasingly large number of human diseases, including liver fibrosis, cirrhosis, and hepatocellular carcinoma. The activation of transforming growth factor β (TGF-β) signaling is considered a critical event during EMT, and efforts have been made to screen small molecules that interfere with the TGF-β signaling pathway during EMT. Here we report the identification of sorafenib, a clinical agent that inhibits TGF-β signaling. When applied to AML12 cells and primary hepatocytes, sorafenib strikingly suppressed TGF-β1-induced EMT and apoptosis. Additionally, sorafenib inhibited TGF-β1-induced signal transducer and activator of transcription 3 phosphorylation. We further present in vitro evidence that sorafenib ameliorates the proapoptotic and profibrotic effects of TGF-β1 in mouse primary hepatocytes, suggesting that this drug exerts a protective effect on hepatocytes and has therapeutic potential for the treatment of liver fibrosis. (HEPATOLOGY 2011;)

作 者:Chen, Yue-Lei; Lv, Jing; Ye, Xiao-Lei; Sun, Ming-Yu; Xu, Qin; Liu, Cheng-Hai; Min, Li-Hua; Li, Hui-Ping; Liu, Ping; Ding, Xiaoyan
期刊名称: Hepatology
期卷页: 2011/05/01 第53卷 第5期 1708~1718页
学科领域:医学科学 » 消化系统 » 肝纤维化、肝硬化与门脉高压症
添加人是否为作者:
原文链接:http://onlinelibrary.wiley.com/doi/10.1002/hep.24254/abstract
DOI: 10.1002/hep.24254
ISBN: 1527-3350
关键词:
相关报道: http://paper.sciencenet.cn/htmlpaper/201151016442197116646.shtm
备 注:
文献笔记

   
导出选项:

评论 (0 个评论)

Page 1 of 1
<<<[1]>>>

举报 | Archiver | 科学网( 京ICP备07017567 )

GMT+8, 2011-2-15 11:31

Powered by ScienceNet.cn

Copyright © 2007- 科学时报社